Placebo News and Research

RSS

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan plc, a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.

4 Nov 2015

Estradiol fluctuation may enhance emotional sensitivity to psychosocial stress during menopausal transition

If you're feeling a little blue during the transition to menopause, there's good reason, according to a new study being reported online today in Menopause, the journal of The North American Menopause Society (NAMS). The study from the Department of Psychiatry at the University of North Carolina at Chapel Hill suggests that the estradiol (a form of estrogen) fluctuation that is common during the menopausal transition may enhance emotional sensitivity to psychosocial stress.

4 Nov 2015

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

4 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders.

30 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015

Study shows restoring testosterone production in men does not impact their fertility

Restoring testosterone production in men may be as effective as replacing it, without compromising their fertility. Two phase III clinical trials show that a drug that restores the body’s natural production of testosterone has no negative effect on a man’s sperm count while a topical testosterone gel causes a significant drop.

28 Oct 2015

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin.

28 Oct 2015

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Insulin plays a much stronger role in regulating release of dopamine

Insulin, the hormone essential to all mammals for controlling blood sugar levels and a feeling of being full after eating, plays a much stronger role than previously known in regulating release of dopamine, a neurotransmitter that helps control the brain's reward and pleasure centers, new studies by researchers at NYU Langone Medical Center show.

27 Oct 2015

Love hormone may enhance pleasure of social interactions, UCI study finds

The hormone oxytocin, which has been associated with interpersonal bonding, may enhance the pleasure of social interactions by stimulating production of marijuana-like neurotransmitters in the brain, according to a University of California, Irvine study.

27 Oct 2015

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

26 Oct 2015

Common steroid medication does not reduce risk of long-term pain after heart surgery

A common steroid medication does not ease long-term pain at the incision site made during open-heart surgery, according to results of a large multicenter randomized controlled trial being presented at the ANESTHESIOLOGY 2015 annual meeting.

26 Oct 2015

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Evidence is mounting that drugs used to treat depression and Alzheimer's disease also can help patients recover from strokes. But there are conflicting findings from studies of these and other drugs given to recovering stroke patients.

22 Oct 2015

Major UK trial to examine role of aspirin in cancer recurrence

The world's largest ever clinical trial looking at whether taking aspirin every day stops some of the most common cancers coming back, launches across the UK today (Thursday).

22 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Leading obesity groups stress need to regulate weight-loss dietary supplements

On the heels of a new study tying dietary supplements to more than 23,000 emergency room visits each year, four leading obesity research, treatment and prevention groups issue a joint scientific statement recommending dietary supplements for weight loss claiming curative or medicinal qualities be subject to review and approval by the United States Food and Drug Administration (FDA).

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Placebo News and Research

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Estradiol fluctuation may enhance emotional sensitivity to psychosocial stress during menopausal transition

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Study shows restoring testosterone production in men does not impact their fertility

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Insulin plays a much stronger role in regulating release of dopamine

Love hormone may enhance pleasure of social interactions, UCI study finds

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Common steroid medication does not reduce risk of long-term pain after heart surgery

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Major UK trial to examine role of aspirin in cancer recurrence

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Leading obesity groups stress need to regulate weight-loss dietary supplements

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News